Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.8% - Should You Sell?

Key Points

• Maze Therapeutics shares fell 5.8% to $25.85, with trading volume well below average. The stock remains below both its 50-day and 200-day moving averages.
• Analyst sentiment is generally positive, with a consensus “Buy” rating and an average price target of $66, although recent ratings included both upgrades and downgrades.
• The company met quarterly EPS expectations at a loss of $0.76 per share, while insiders sold about $3.1 million in stock over the past three months—transactions conducted under pre-arranged trading plans.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price fell 5.8% during trading on Monday . The stock traded as low as $25.85 and last traded at $25.85. Approximately 203,386 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 642,078 shares. The stock had previously closed at $27.44.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research restated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $66.00.

Maze Therapeutics Price Performance

The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -10.28 and a beta of 2.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The stock's fifty day moving average price is $28.74 and its 200-day moving average price is $31.79.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.76). Equities research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Transactions at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the transaction, the chief executive officer directly owned 23,337 shares in the company, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the sale, the chief marketing officer owned 16,142 shares of the company's stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 108,110 shares of company stock valued at $3,057,531 in the last three months. Corporate insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Maze Therapeutics in the 1st quarter valued at approximately $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics during the first quarter worth about $145,000. Rhumbline Advisers acquired a new position in Maze Therapeutics during the first quarter worth approximately $80,000. Geode Capital Management LLC raised its stake in Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company's stock valued at $2,838,000 after buying an additional 18,773 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after buying an additional 3,371 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source